Summary
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.14 per share a year ago.
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Sangamo Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 1,525 | $546 | $115.9 | -$430.1 | -78.77% |
 Anthony Scaramucci SkyBridge Capital II LLC | 40.4M | $9.97M | $3.07M | -$6.9M | -69.22% |
| RS Richard Slavik Newbridge Financial Services Group Inc. | 6,000 | $1,481.4 | $456 | -$1,025.4 | -69.22% |
| SE Sima Elimelech Activest Wealth Management | 1,000 | $358.3 | $76 | -$282.3 | -78.79% |
| AB Andrew Blass Atlantic Private Wealth LLC | 1,000 | $866.1 | $76 | -$790.1 | -91.23% |
Sangamo Therapeutics Inc. (SGMO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sangamo Therapeutics Inc. ever had a stock split?
Sangamo Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alexander D. Macrae Ch.B CEO | OTC PINK Exchange | 800677106 CUSIP |
| US Country | 127 Employees | - Last Dividend | - Last Split | 6 Apr 2000 IPO Date |
Overview
Sangamo Therapeutics, Inc. is recognized as a pioneering force in the field of genomic medicine, embarking on the ambitious journey of converting scientific breakthroughs into transformative treatments for individuals afflicted with severe diseases across the United States. Originating in 1995 and undergoing a significant rebranding from Sangamo BioSciences, Inc. to Sangamo Therapeutics, Inc. in January 2017, the company has established its headquarters in Brisbane, California. Through its various collaborative and strategic partnerships with leading entities such as Biogen MA, Inc., Pfizer Inc., and Sanofi S.A., among others, Sangamo stands at the forefront of addressing unmet medical needs by advancing a diverse portfolio of therapeutic candidates through clinical development.
Products and Services
- ST-920 (Gene Therapy for Fabry Disease)
ST-920 is advancing through Phase 1/2 clinical trials as a gene therapy candidate aimed at treating Fabry disease, a genetic condition that impairs the body's ability to break down specific fatty substances.
- TX200 (CAR-Treg Therapy for Kidney Transplantation)
A cutting-edge chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy, TX200 is in Phase 1/2 clinical study. It is designed for the prevention of immune-mediated rejection in patients undergoing HLA-A2 mismatched kidney transplantation.
- SB-525 (Gene Therapy for Hemophilia A)
Targeting the treatment of moderately severe to severe hemophilia A, SB-525 is a gene therapy product in a pivotal Phase 3 clinical trial. This therapy seeks to deliver a functional form of the factor VIII gene to patients, addressing the underlying cause of this bleeding disorder.
- BIVV003 (Zinc Finger Nuclease Gene-Edited Cell Therapy for Sickle Cell Disease)
Engaged in the Phase 1/2 PRECIZN-1 clinical study, BIVV003 represents a pioneering approach to treating sickle cell disease. This zinc finger nuclease gene-edited cell therapy aims to correct the genetic mutation in hematopoietic stem cells that causes the disease.
In addition to its clinical-stage candidates, Sangamo Therapeutics, Inc. is also deeply invested in preclinical development efforts. These include CAR-Treg cell therapies targeting autoimmune disorders and groundbreaking genome engineering techniques to tackle neurological diseases, positioning the company as an innovator in genomic medicine.
